Log in

Relevant bibliographies by topics / Anti-anginal / Journal articles

To see the other types of publications on this topic, follow the link: Anti-anginal.

Journal articles on the topic 'Anti-anginal'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anti-anginal.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cavallino, Chiara, Manuela Facchini, Alessia Veia, et al. "New Anti-Anginal Drugs: Ranolazine." Cardiovascular & Hematological Agents in Medicinal Chemistry 13, no. 1 (2015): 14–20. http://dx.doi.org/10.2174/1871525713666141219112841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lardizabal, Joel A., and Prakash C. Deedwania. "The Anti-Ischemic and Anti-Anginal Properties of Statins." Current Atherosclerosis Reports 13, no. 1 (2010): 43–50. http://dx.doi.org/10.1007/s11883-010-0147-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Aldakkak, Mohammed, David F. Stowe, and Amadou K. S. Camara. "Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris." Clinical Medicine Insights: Therapeutics 5 (January 2013): CMT.S7824. http://dx.doi.org/10.4137/cmt.s7824.

Full text

Abstract:

Coronary heart disease is a global malady and it is the leading cause of death in the United States. Chronic stable angina is the most common manifestation of coronary heart disease and it results from the imbalance between myocardial oxygen supply and demand due to reduction in coronary blood flow. Therefore, in addition to lifestyle changes, commonly used pharmaceutical treatments for angina (nitrates, β-blockers, Ca2+ channel blockers) are aimed at increasing blood flow or decreasing O2 demand. However, patients may continue to experience symptoms of angina. Ranolazine is a relatively new d

APA, Harvard, Vancouver, ISO, and other styles

4

Dorow, P., and W. Schiess. "The acute anti-anginal efficacy of bopindolol." Current Opinion in Cardiology 3 (January 1988): S113—S116. http://dx.doi.org/10.1097/00001573-198801002-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Julian, D. G. "Comparisons and Combinations in Anti-Anginal Therapy." European Heart Journal 6, suppl A (1985): 37–45. http://dx.doi.org/10.1093/eurheartj/6.suppl_a.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Schmutzler, H. "Alternative Anti-Anginal Drugs: Amiodarone and Molsidomine." European Heart Journal 6, suppl F (1985): 77–82. http://dx.doi.org/10.1093/eurheartj/6.suppl_f.77.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nyberg, GunnarF. "Duration of efficacy of anti-anginal drugs." Lancet 339, no. 8788 (1992): 307. http://dx.doi.org/10.1016/0140-6736(92)91378-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Малыгина, V. Malygina, Сергунина, et al. "Evaluation of effect of the coronater drug on the indices of deformation of the left ventricular myocardium in patients with chd." Journal of New Medical Technologies. eJournal 8, no. 1 (2014): 0. http://dx.doi.org/10.12737/7364.

Full text

Abstract:

Currently, the methods of early diagnosis and treatment of stable angina are of interest to researchers. One of the methods of diagnosis is echocardiography using a two-dimensional speckle tracking. Technology speckle tracking allows to evaluate systolic and diastolic heart function in various cardiovascular diseases, including coronary heart disease (CHD). By means of this program all types of myocardial deformation: radial, circular, longitudinal, the rate of deformation and rotation of the myocardium can be evaluated. The clinical studies have shown that changes in the indices of deformatio

APA, Harvard, Vancouver, ISO, and other styles

9

Chandankhede, Tejas. "Case Report on chronic cardiac failure & hyperthyroidism & bronchial asthma." Journal of RURAL NURSING 10, no. 2 (2022): 65–67. http://dx.doi.org/10.54054/jrn.202210217.

Full text

Abstract:

Heart failure is a long-term, development of a progressive ailment when the The heart’s muscle cannot to sufficient blood pump to meet the body’s needs for oxygen and blood. Essentially, The heart cannot do it to withstand the stress. A 75 year old women admitted in AVBR hospital with the chief complaints breathlessness , cough, fever, pain in thoracic region , hypertension, etc. During her hospital stay, the patient received the patient’s major therapeutic intervention and was treated with intravenous anti-anginal medicines, injection antiemetics, NSAIDs,etc .Categories : anti anginal drugs ,

APA, Harvard, Vancouver, ISO, and other styles

10

Shehata, Mohamed. "Nicorandil: What is Beyond the Anti-Anginal Action?" Heart Research - Open Journal 2, no. 4 (2015): e6-e8. http://dx.doi.org/10.17140/hroj-2-e003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Pavasini, Rita, Paolo G. Camici, Filippo Crea, et al. "Anti-anginal drugs: Systematic review and clinical implications." International Journal of Cardiology 283 (May 2019): 55–63. http://dx.doi.org/10.1016/j.ijcard.2018.12.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Wimmer, Neil J., and Peter H. Stone. "Anti-Anginal and Anti-Ischemic Effects of Late Sodium Current Inhibition." Cardiovascular Drugs and Therapy 27, no. 1 (2012): 69–77. http://dx.doi.org/10.1007/s10557-012-6431-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kumar, Rajesh, Chakrapani Kumar, Pramod Kumar Manjhi, Akhilesh Kumar Rana, and Shuvasree Payra. "Economic Evaluation of Different Brands of Commonly Prescribed Drugs Used in the Management of Angina Pectoris in Indian Market." International Journal of Current Research and Review 15, no. 06 (2023): 01–05. http://dx.doi.org/10.31782/ijcrr.2023.15601.

Full text

Abstract:

Introduction: Coronary artery disease (CAD) is one of the most common causes of cardiovascular mortality and morbidity in developing countries like India. Initial management includes use of many anti- anginal drugs. If angina pectoris not managed adequately results in significant morbidity and mortality too due to the complications. Anti-anginal drugs are used for lifelong. Therefore, analysis of the price of different drugs used in ischemic heart disease will help to improve patient compliance. Objective: (1) To assess the cost variation of different drugs available as antianginal agents in I

APA, Harvard, Vancouver, ISO, and other styles

14

Pasupathy, Sivabaskari, Rosanna Tavella, Christopher Zeitz, et al. "Anti-Anginal Efficacy of Zibotentan in the Coronary Slow-Flow Phenomenon." Journal of Clinical Medicine 13, no. 5 (2024): 1337. http://dx.doi.org/10.3390/jcm13051337.

Full text

Abstract:

Background: Patients with coronary microvascular disorders often experience recurrent angina for which there are limited evidence-based therapies. These patients have been found to exhibit increased plasma levels of endothelin; thus, selective endothelin–A (Et-A) receptor blockers such as zibotentan may be an effective anti-anginal therapy in these patients. The study evaluated the impact of a 10 mg daily dose of zibotentan on spontaneous angina episodes in patients with the coronary slow-flow phenomenon who had refractory angina (i.e., experiencing angina at least three times/week despite cur

APA, Harvard, Vancouver, ISO, and other styles

15

Pasupathy, Sivabaskari, Rosanna Tavella, Christopher Zeitz, et al. "Randomised Placebo-Controlled Pilot Trial Evaluating the Anti-Anginal Efficacy of Ticagrelor in Patients with Angina with Nonobstructive Coronary Arteries and Coronary Slow Flow Phenomenon." Journal of Clinical Medicine 13, no. 17 (2024): 5235. http://dx.doi.org/10.3390/jcm13175235.

Full text

Abstract:

Background: The coronary slow flow phenomenon (CSFP) is an angiographic finding characterised by the delayed passage of contrast through the coronary arteries, despite the absence of obstructive coronary artery disease (defined as less than 50% narrowing of the vessel lumen). Patients with the CSFP experience recurrent angina, for which there are limited evidence-based therapies. Ticagrelor may serve as an effective anti-anginal therapy for these patients by increasing adenosine levels, which could alleviate coronary microvascular dysfunction and its associated angina due to its vasodilatory p

APA, Harvard, Vancouver, ISO, and other styles

16

SCHULTE, K. L. "24 h anti-anginal and anti-ischaemic effects with once daily felodipine." European Heart Journal 16, no. 2 (1995): 171–76. http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a060881.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Reffelmann, Thorsten, and Robert A. Kloner. "Ranolazine: an anti-anginal drug with further therapeutic potential." Expert Review of Cardiovascular Therapy 8, no. 3 (2010): 319–29. http://dx.doi.org/10.1586/erc.09.178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cooper, J. D. H., D. C. Turnell, J. Pilcher, and D. Lockhart. "Therapeutic Monitoring of the Anti-Anginal Drug Perhexiline Maleate." Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine 22, no. 6 (1985): 614–17. http://dx.doi.org/10.1177/000456328502200611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

LAM, A., and G. LOPASCHUK. "Anti-anginal effects of partial fatty acid oxidation inhibitors." Current Opinion in Pharmacology 7, no. 2 (2007): 179–85. http://dx.doi.org/10.1016/j.coph.2006.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

S., Madhumitha V. Karan*. "Novel Drugs Approach in Treatment of Angina." International Journal of Scientific Research and Technology 2, no. 3 (2025): 477–82. https://doi.org/10.5281/zenodo.15085105.

Full text

Abstract:

Angina Pectoris is a common symptom of ischemic heart disease. In 1772 according to William Heberden Angina is characterized by the painful and disagreeable sensation that occurs in the breast during walking. This is caused as the result of the myocardial oxygen supply and demand imbalance.  The oxygen demand increases due to tachycardia, hypertension, left ventricular hypertrophy.  Tissue ischemia leads to series of metabolic changes which includes elevated intracellular lactate production and acidification that produces anginal symptoms.  Besides coronary obstructive diseases,

APA, Harvard, Vancouver, ISO, and other styles

21

Detry, J. M. "Clinical features of an anti-anginal drug in angina pectoris." European Heart Journal 14, suppl G (1993): 18–24. http://dx.doi.org/10.1093/eurheartj/14.suppl_g.18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ansari, Sana, M. Shahnawaze Ansari, Neshtha Dev, and Soami P. Satsangee. "CeO2 nanoparticles based electrochemical sensor for an anti-anginal drug." Materials Today: Proceedings 18 (2019): 1210–19. http://dx.doi.org/10.1016/j.matpr.2019.06.583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Rousan, Talla A., Sunil T. Mathew, and Udho Thadani. "The risk of cardiovascular side effects with anti-anginal drugs." Expert Opinion on Drug Safety 15, no. 12 (2016): 1609–23. http://dx.doi.org/10.1080/14740338.2016.1238457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Jain, Rajeev, and Rajeev Kumar Yadav. "Voltammetric assay of anti-anginal drug nicorandil in different solvents." Drug Testing and Analysis 3, no. 3 (2010): 171–75. http://dx.doi.org/10.1002/dta.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Iablonska, Victoriia, Leonid Kholopov, Olena Khyzhnyak, and Viktoriia Batashova-Halinska. "The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime." ScienceRise: Medical Science, no. 6 (51) (November 30, 2022): 4–7. http://dx.doi.org/10.15587/2519-4798.2022.268523.

Full text

Abstract:

The aim of the study is to establish the effectiveness of treatment of severe angina pectoris in patients with hyperuricemia, taking into consideration the peculiarities of the course of coronary artery disease (CAD) in wartime, using ranolazine – a selective inhibitor of the late sodium flow in combined pharmacotherapy. Materials and methods. We studied the anti-anginal effect of ranolazine in 14 patients with CAD, stable angina pectoris III-IV functional class (FC), hyperuricemia and arterial hypertension (AH) during 6 months of the 2022 year. The effectiveness of the study drug on the

APA, Harvard, Vancouver, ISO, and other styles

26

Zadionchenko, V. S., G. G. Shehyan, A. A. Yalymov, and S. I. Varentsov. "The use of ranolazine in the treatment of coronary heart disease." CardioSomatics 5, no. 3-4 (2014): 48–53. http://dx.doi.org/10.26442/cs45130.

Full text

Abstract:

The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patients with stable angina during treatment with ranolazine. Discusses indications, contraindications, side effects, as well as the major clinical trials of the drug ranolazine in patients with coronary heart disease.

APA, Harvard, Vancouver, ISO, and other styles

27

Zavalskaya, T. V., and V. V. Bogdan. "Influence of antianginal therapy and L-arginine on serum essential aminoacids spectrum among patients with unstable angina." Likarska sprava, no. 1-2 (March 26, 2019): 63–68. http://dx.doi.org/10.31640/jvd.1-2.2019(9).

Full text

Abstract:

The patients with unstable angina (UA) were examined using the method of ion exchange liquid-column chromatography. The content of the substitutable amino acids (AA) in blood serum was determined: ornithine, taurine, aspartic acid, serine, glutamic acid, proline, glycine, alanine, cysteine, tyrosine, glutamine. The patients were divided into two groups: І – 37 people who received cardicet, bisoprolol, atoris, enap, acetylsalicylic acid, clopidogrel; ІІ – 38 people, the therapy of which, in addition to the mentioned drugs, included L-arginine (100 ml intravenous for 10 days). The results of the

APA, Harvard, Vancouver, ISO, and other styles

28

Victoriia, Iablonska, Kholopov Leonid, Khyzhnyak Olena, and Batashova-Halinska Viktoriia. "The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime." ScienceRise: Medical Science, no. 6(51) (November 30, 2022): 4–7. https://doi.org/10.15587/2519-4798.2022.268523.

Full text

Abstract:

<strong>The aim</strong> of the study is to establish the effectiveness of treatment of severe angina pectoris in patients with hyperuricemia, taking into consideration the peculiarities of the course of coronary artery disease (CAD) in wartime, using ranolazine – a selective inhibitor of the late sodium flow in combined pharmacotherapy. <strong>Materials and methods. </strong>We studied the anti-anginal effect of ranolazine in 14 patients with CAD, stable angina pectoris III-IV functional class (FC), hyperuricemia and arterial hypertension (AH) during 6 months of the 2022 year

APA, Harvard, Vancouver, ISO, and other styles

29

Serruys, P. W., P. De Feyter, A. Soward, D. Amidi, and R. Brower. "Does PTCA or CABG Reduce the Usage of Anti-Anginal Medications?" European Heart Journal 6, suppl F (1985): 87–90. http://dx.doi.org/10.1093/eurheartj/6.suppl_f.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

van Zwieten, Pieter A. "Clinical pharmacology of calcium antagonists as antihypertensive and anti-anginal drugs." Journal of Hypertension 14, supplement 3 (1996): S3—S9. http://dx.doi.org/10.1097/00004872-199610003-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Asai, Tomoyuki, Yoshitomi Morizawa, Toyomichi Shimada, et al. "Synthesis of new stable fluoroprostacyclin analogs with potent anti-anginal activity." Tetrahedron Letters 36, no. 2 (1995): 273–76. http://dx.doi.org/10.1016/0040-4039(94)02217-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tritto, Isabella, Penghai Wang, Periannan Kuppusamy, Roberto Giraldez, Jay L. Zweier, and Giuseppe Ambrosio. "The Anti-Anginal Drug Trimetazidine Reduces Neutrophil-Mediated Cardiac Reperfusion Injury." Journal of Cardiovascular Pharmacology 46, no. 1 (2005): 89–98. http://dx.doi.org/10.1097/01.fjc.0000164091.81198.a3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kobrin, Isaac, Gabriele Bieska, Vincent Charlon, Elisabet Lindberg, and Robert Pordy. "Anti-Anginal and Anti-Ischemic Effects of Mibefradil, a New T-Type Calcium Channel Antagonist." Cardiology 89, no. 1 (1998): 23–32. http://dx.doi.org/10.1159/000047276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

De Santis, Giulia Azzurra, Tommaso De Ferrari, Francesca Parisi, et al. "Ranolazine Unveiled: Rediscovering an Old Solution in a New Light." Journal of Clinical Medicine 13, no. 17 (2024): 4985. http://dx.doi.org/10.3390/jcm13174985.

Full text

Abstract:

Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine’s mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.

APA, Harvard, Vancouver, ISO, and other styles

35

Ricci, Fabrizio, Federico Archilletti, and Raffaele De Caterina. "Diagnostic and therapeutic approach to the ACS patient." Global & Regional Health Technology Assessment 9, Suppl. 1 (2022): 2–13. http://dx.doi.org/10.33393/grhta.2022.2389.

Full text

Abstract:

The current management strategy of acute coronary syndromes aims at symptoms relief as well as at specifically antagonizing each of the different pathogenic components of myocardial ischemia, including the pro-thrombotic state, poor coronary flow and myocardial damage. Different approaches are available, including revascularization procedures and pharmacological interventions. Various anti-anginal, anti-thrombotic and anti-coagulant drugs can be used according to individual features and needs, as well as secondary prevention measures based on statin use and ACE-inhibition. The appropriate use

APA, Harvard, Vancouver, ISO, and other styles

36

McCreanor, Victoria, Alexandra Nowbar, Christopher Rajkumar, et al. "Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial." BMJ Open 11, no. 2 (2021): e044054. http://dx.doi.org/10.1136/bmjopen-2020-044054.

Full text

Abstract:

ObjectiveTo evaluate the cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina despite anti-anginal therapy.DesignA cost-effectiveness analysis comparing PCI with placebo. A Markov model was used to measure incremental cost-effectiveness, in cost per quality-adjusted life-years (QALYs) gained, over 12 months. Health utility weights were estimated using responses to the EuroQol 5-level questionnaire, from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in s

APA, Harvard, Vancouver, ISO, and other styles

37

Hansson, L. "Factors in the selection of a new antihypertensive and anti-anginal drug." Current Opinion in Cardiology 3 (January 1988): S3—S6. http://dx.doi.org/10.1097/00001573-198801002-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

McCarthy, Cian P., Kieran V. Mullins, and David M. Kerins. "The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent." European Heart Journal - Cardiovascular Pharmacotherapy 2, no. 4 (2015): 266–72. http://dx.doi.org/10.1093/ehjcvp/pvv051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Riise Moen, Anders, Rasmus Karstad, and Thorleif Anthonsen. "Chemo-enzymatic synthesis of both enantiomers of the anti-anginal drug ranolazine." Biocatalysis and Biotransformation 23, no. 1 (2005): 45–51. http://dx.doi.org/10.1080/10242420500067357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Baker, Jillian G., Stephen J. Hill та Roger J. Summers. "Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling". Trends in Pharmacological Sciences 32, № 4 (2011): 227–34. http://dx.doi.org/10.1016/j.tips.2011.02.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Jain, D., A. Lahiri, P. Dasgupta, L. O. Hughes, and E. B. Raftery. "Rs-43285 (Syntex) A Preliminary Study of A Unique Anti-Anginal Agent." Clinical Science 73, s17 (1987): 38P. http://dx.doi.org/10.1042/cs073038pa.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Pasupathy, S., R. Tavekka, C. Zeitz, et al. "Anti Anginal Efficacy of Zibotentan in Coronary Microvascular Dysfunction—A Pilot Study." Heart, Lung and Circulation 32 (July 2023): S268. http://dx.doi.org/10.1016/j.hlc.2023.06.341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Sushil, Kumar, Kumari Asha, and Babu Raman Ram. "A Cross Sectional Observational Assessment of the Prescription Pattern in Ischemic Heart Disease." International Journal of Toxicological and Pharmacological Research 13, no. 6 (2023): 168–73. https://doi.org/10.5281/zenodo.11160988.

Full text

Abstract:

<strong>Aim: </strong>The aim of the present study was to analyze the drug prescribing pattern for treatment of ischemic heart disease. <strong>Methods: </strong>This was a cross sectional observational study conducted on ischemic heart disease patients admitted at inpatient department of Medicine in Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India for 18 months. The study consisted of analysis of drug utilization pattern of prescribed drugs. A total number of 200 patients were enrolled in the study. <strong>Results: </strong>IHD was more c

APA, Harvard, Vancouver, ISO, and other styles

44

Tardif, Jean-Claude. "Safety and Efficacy of Ivabradine in the Management of Stable Angina Pectoris." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S1086. http://dx.doi.org/10.4137/cmt.s1086.

Full text

Abstract:

The first selective If current inhibitor, ivabradine, lowers heart rate (HR) at rest and during exercise with no vasomotor, negative inotropic, or negative lusitropic effects. Given that elevated resting HR is a key factor in the onset of myocardial ischemia and a strong independent predictor of cardiovascular outcomes, ivabradine provides new therapeutic prospects in coronary artery disease (CAD). Its selective HR-lowering action has proven anti-ischemic and anti-anginal efficacy, and ivabradine is currently indicated for the symptomatic treatment of stable angina pectoris. Ivabradine can als

APA, Harvard, Vancouver, ISO, and other styles

45

Al-Lamee, Rasha K., Alexandra N. Nowbar, and Darrel P. Francis. "Percutaneous coronary intervention for stable coronary artery disease." Heart 105, no. 1 (2018): 11–19. http://dx.doi.org/10.1136/heartjnl-2017-312755.

Full text

Abstract:

The adverse consequences of stable coronary artery disease (CAD) are death, myocardial infarction (MI) and angina. Trials in stable CAD show that percutaneous coronary intervention (PCI) does not reduce mortality. PCI does appear to reduce spontaneous MI rates but at the expense of causing some periprocedural MI. Therefore, the main purpose of PCI is to relieve angina. Indeed, patients and physicians often choose PCI rather than first attempting to control symptoms with anti-anginal medications as recommended by guidelines. Nevertheless, it is unclear how effective PCI is at relieving angina.

APA, Harvard, Vancouver, ISO, and other styles

46

Abbas, Eslam, Ahmed Mahdy, and Shady Mansy. "Relentless Angina of a Scarred Heart." Cardiology and Cardiovascular Research 8, no. 4 (2024): 92–95. https://doi.org/10.11648/j.ccr.20240804.11.

Full text

Abstract:

Refractory anginal pain affects nearly 5-10% of stable coronary artery disease patients, and maximizing the anti-ischemic medical therapy is the standard first-line treatment. The presence of a scarred myocardial territory of the epicardial coronary chronic total occlusion (CTO) limits the implementation of other modalities, such as angioplasty and surgical bypass. Accordingly, this subset of patients, who show poor response to medical treatment with the absence of considerable reversible ischemia, bears an additional burden of persistent angina besides the structural and functional complicati

APA, Harvard, Vancouver, ISO, and other styles

47

Takahashi, Kenzo, Satomi Kishi, Teisuke Takahashi, Katsuharu Tsuchida, and Susumu Otomo. "Anti-anginal effect of CD-832, a novel Ca antagonist, in anesthetized dogs." Japanese Journal of Pharmacology 58 (1992): 399. http://dx.doi.org/10.1016/s0021-5198(19)49691-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Mulcahy, David, David Cunningham, Peter Crean, et al. "CIRCADIAN VARIATION OF TOTAL ISCHAEMIC BURDEN AND ITS ALTERATION WITH ANTI-ANGINAL AGENTS." Lancet 332, no. 8614 (1988): 755–59. http://dx.doi.org/10.1016/s0140-6736(88)92414-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lin, Muh-Chiou, and Chung-Ren Jan. "The anti-anginal drug fendiline elevates cytosolic Ca2+ in rabbit corneal epithelial cells." Life Sciences 71, no. 9 (2002): 1071–79. http://dx.doi.org/10.1016/s0024-3205(02)01797-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Niemann, Troels, Torsten Toftegaard Nielsen, Niels Thorsgaard, Tavs Folmer Andersen, and Jørgen Lous. "Prescription of anti-anginal drugs in relation to exercise tests and coronary angiography." European Journal of Internal Medicine 13, no. 8 (2002): 500–506. http://dx.doi.org/10.1016/s0953-6205(02)00159-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!